title: Hepatectomy for resectable colorectal cancer metastases--indicators of prognosis, definition of resectability, techniques and outcomes.
abstract: The field of surgery for liver metastases is evolving rapidly. The proportion of patients viewed as amenable to resection is increasing with surgeons becoming more aggressive and systemic therapy more effective. Surgical resection is associated with low mortality and overall 5-year survival approaching 40%. Best candidates for resection are those with stage I or II colorectal cancer, fewer than 4 hepatic lesions, no lesions larger than 5 cm in diameter, no evidence of extra-hepatic disease, CEA level less than 5 ng/mL, and a disease-free interval of at least 2 years. Perioperative chemotherapy with or without biotherapies, in-situ ablation techniques, portal vein embolization, and staged hepatectomy have extended the indications without lessening the results of liver resection for colorectal metastases.
authors.affiliation: Hôpital Ambroise-Paré, Service de Chirurgie Digestive, 9 av Charles De Gaulle, 92100 Boulogne Billancourt, France.
authors.forename: Renato
authors.initials: R
authors.lastname: Lupinacci
authors.forename: Christophe
authors.initials: C
authors.lastname: Penna
authors.forename: Bernard
authors.initials: B
authors.lastname: Nordlinger
mesh_terms: D002272:Carcinoembryonic Antigen / Q000097:blood; D015179:Colorectal Neoplasms / Q000473:pathology* / Q000601:surgery; D018572:Disease-Free Survival; D006498:Hepatectomy / Q000379:methods*; D006801:Humans; D008099:Liver / Q000473:pathology* / Q000503:physiopathology / Q000601:surgery; D008113:Liver Neoplasms / Q000503:physiopathology / Q000556:secondary / Q000601:surgery*; D009367:Neoplasm Staging; D011183:Postoperative Complications; D011379:Prognosis; D012086:Reoperation; D016896:Treatment Outcome
chemical_list: D002272:Carcinoembryonic Antigen